🇪🇺 Dynepo in European Union

EMA authorised Dynepo on 18 March 2002

Marketing authorisation

EMA — authorised 18 March 2002

  • Application: EMEA/H/C/000372
  • Marketing authorisation holder: Shire Pharmaceutical Contracts Limited
  • Local brand name: Dynepo
  • Indication: Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.
  • Status: withdrawn

Read official source →

Dynepo in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Dynepo approved in European Union?

Yes. EMA authorised it on 18 March 2002.

Who is the marketing authorisation holder for Dynepo in European Union?

Shire Pharmaceutical Contracts Limited holds the EU marketing authorisation.